Search This Blog

Monday, June 1, 2026

Turn Therapeutics reports positive interim Phase 2 GX-03 data in moderate-to-severe atopic dermatitis

 

Turn Therapeutics reports positive interim Phase 2 GX-03 data in moderate-to-severe atopic dermatitis with strong early efficacy and favorable safety

  • Company highlights an optimized trial and regulatory strategy moving forward based on the interim Phase 2 GX-03 data.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)